381 related articles for article (PubMed ID: 9258227)
1. An aldose reductase inhibitor and aminoguanidine prevent vascular endothelial growth factor expression in rats with long-term galactosemia.
Frank RN; Amin R; Kennedy A; Hohman TC
Arch Ophthalmol; 1997 Aug; 115(8):1036-47. PubMed ID: 9258227
[TBL] [Abstract][Full Text] [Related]
2. Diabetic-like retinopathy ameliorated with the aldose reductase inhibitor WAY-121,509.
Robinson WG; Laver NM; Jacot JL; Glover JP; Basso MD; Blouin P; Hohman TC
Invest Ophthalmol Vis Sci; 1996 May; 37(6):1149-56. PubMed ID: 8631629
[TBL] [Abstract][Full Text] [Related]
3. Retinopathy and tissue hexose in drug-treated animals.
Engerman RL; Kern TS
Arch Ophthalmol; 1998 Apr; 116(4):543-4. PubMed ID: 9565062
[No Abstract] [Full Text] [Related]
4. Vascular endothelial growth factor is present in glial cells of the retina and optic nerve of human subjects with nonproliferative diabetic retinopathy.
Amin RH; Frank RN; Kennedy A; Eliott D; Puklin JE; Abrams GW
Invest Ophthalmol Vis Sci; 1997 Jan; 38(1):36-47. PubMed ID: 9008628
[TBL] [Abstract][Full Text] [Related]
5. Galactose-induced retinal microangiopathy in rats.
Kern TS; Engerman RL
Invest Ophthalmol Vis Sci; 1995 Feb; 36(2):490-6. PubMed ID: 7843917
[TBL] [Abstract][Full Text] [Related]
6. Response of capillary cell death to aminoguanidine predicts the development of retinopathy: comparison of diabetes and galactosemia.
Kern TS; Tang J; Mizutani M; Kowluru RA; Nagaraj RH; Romeo G; Podesta F; Lorenzi M
Invest Ophthalmol Vis Sci; 2000 Nov; 41(12):3972-8. PubMed ID: 11053301
[TBL] [Abstract][Full Text] [Related]
7. Diabetic-like retinopathy: early and late intervention therapies in galactose-fed rats.
Robison WG; Jacot JL; Glover JP; Basso MD; Hohman TC
Invest Ophthalmol Vis Sci; 1998 Sep; 39(10):1933-41. PubMed ID: 9727416
[TBL] [Abstract][Full Text] [Related]
8. A biodegradable injectable implant sustains systemic and ocular delivery of an aldose reductase inhibitor and ameliorates biochemical changes in a galactose-fed rat model for diabetic complications.
Aukunuru JV; Sunkara G; Ayalasomayajula SP; DeRuiter J; Clark RC; Kompella UB
Pharm Res; 2002 Mar; 19(3):278-85. PubMed ID: 11934234
[TBL] [Abstract][Full Text] [Related]
9. Increases in collagen type IV and laminin in galactose-induced retinal capillary basement membrane thickening--prevention by an aldose reductase inhibitor.
Das A; Frank RN; Zhang NL; Samadani E
Exp Eye Res; 1990 Mar; 50(3):269-80. PubMed ID: 2108050
[TBL] [Abstract][Full Text] [Related]
10. Retinal capillary dilation: early diabetic-like retinopathy in the galactose-fed rat model.
Glover JP; Jacot JL; Basso MD; Hohman TC; Robison WG
J Ocul Pharmacol Ther; 2000 Apr; 16(2):167-72. PubMed ID: 10803427
[TBL] [Abstract][Full Text] [Related]
11. Diabetic-like retinopathy in rats prevented with an aldose reductase inhibitor.
Robison WG; Nagata M; Laver N; Hohman TC; Kinoshita JH
Invest Ophthalmol Vis Sci; 1989 Nov; 30(11):2285-92. PubMed ID: 2509395
[TBL] [Abstract][Full Text] [Related]
12. A selective aldose reductase inhibitor of a new structural class prevents or reverses early retinal abnormalities in experimental diabetic retinopathy.
Sun W; Oates PJ; Coutcher JB; Gerhardinger C; Lorenzi M
Diabetes; 2006 Oct; 55(10):2757-62. PubMed ID: 17003340
[TBL] [Abstract][Full Text] [Related]
13. Sorbinil prevention of diabetic-like retinopathy in the galactose-fed rat model.
Robison WG; Laver NM; Jacot JL; Glover JP
Invest Ophthalmol Vis Sci; 1995 Nov; 36(12):2368-80. PubMed ID: 7591626
[TBL] [Abstract][Full Text] [Related]
14. Correction of early subnormal superior hemiretinal DeltaPO(2) predicts therapeutic efficacy in experimental diabetic retinopathy.
Berkowitz BA; Ito Y; Kern TS; McDonald C; Hawkins R
Invest Ophthalmol Vis Sci; 2001 Nov; 42(12):2964-9. PubMed ID: 11687543
[TBL] [Abstract][Full Text] [Related]
15. Effects of aldose reductase inhibitors and galactose withdrawal on fluorescein angiographic lesions in galactose-fed dogs.
Cusick M; Chew EY; Ferris F; Cox TA; Chan CC; Kador PF
Arch Ophthalmol; 2003 Dec; 121(12):1745-51. PubMed ID: 14662595
[TBL] [Abstract][Full Text] [Related]
16. Galactosemia produces ARI-preventable nodal changes similar to those of diabetic neuropathy.
Kamijo M; Basso M; Cherian PV; Hohman TC; Sima AA
Diabetes Res Clin Pract; 1994 Sep; 25(2):117-29. PubMed ID: 7821191
[TBL] [Abstract][Full Text] [Related]
17. Diabetes-related histopathologies of the rat retina prevented with an aldose reductase inhibitor.
Robison WG; Tillis TN; Laver N; Kinoshita JH
Exp Eye Res; 1990 Apr; 50(4):355-66. PubMed ID: 2110907
[TBL] [Abstract][Full Text] [Related]
18. Aldose reductase inhibitor fidarestat attenuates leukocyte-endothelial interactions in experimental diabetic rat retina in vivo.
Hattori T; Matsubara A; Taniguchi K; Ogura Y
Curr Eye Res; 2010 Feb; 35(2):146-54. PubMed ID: 20136425
[TBL] [Abstract][Full Text] [Related]
19. Glycolytic pathway, redox state of NAD(P)-couples and energy metabolism in lens in galactose-fed rats: effect of an aldose reductase inhibitor.
Obrosova I; Faller A; Burgan J; Ostrow E; Williamson JR
Curr Eye Res; 1997 Jan; 16(1):34-43. PubMed ID: 9043821
[TBL] [Abstract][Full Text] [Related]
20. Abnormalities of retinal metabolism in diabetes or experimental galactosemia VIII. Prevention by aminoguanidine.
Kowluru RA; Engerman RL; Kern TS
Curr Eye Res; 2000 Oct; 21(4):814-9. PubMed ID: 11120572
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
